Cargando…

A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease

BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattori, Nobutaka, Kitabayashi, Hiroki, Kanda, Tomoyuki, Nomura, Takanobu, Toyama, Keizo, Mori, Akihisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496465/ https://www.ncbi.nlm.nih.gov/pubmed/32501582 http://dx.doi.org/10.1002/mds.28095

Ejemplares similares

Istradefylline for Restless Legs Syndrome Associated with Parkinson’s Disease
por: Nuermaimaiti, Maierdanjiang, et al.
Publicado: (2018)

Adenosine A(2A) Receptor Occupancy by Long‐Term Istradefylline Administration in Parkinson's Disease
por: Ishibashi, Kenji, et al.
Publicado: (2020)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

Istradefylline effects on tremor dominance (TD) and postural instability and gait difficulty (PIGD)
por: Torres-Yaghi, Yasar, et al.
Publicado: (2023)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

The effect of istradefylline for Parkinson’s disease: A meta-analysis
por: Sako, Wataru, et al.
Publicado: (2017)

Istradefylline Improves Impaired Smooth Pursuit Eye Movements in Parkinson’s Disease
por: Fujita, Youshi, et al.
Publicado: (2023)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
por: Berger, Amnon A., et al.
Publicado: (2020)

Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios
por: Isaacson, Stuart H, et al.
Publicado: (2022)

Separation and identification of an impurity from the istradefylline intermediate
por: Xu, Haojie, et al.
Publicado: (2020)

Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Singh, Alok, et al.
Publicado: (2021)

α‐Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a Weaker Lipid‐Binding Property
por: Daida, Kensuke, et al.
Publicado: (2022)

Adenosine A(2A) receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease
por: Mizuno, Yoshikuni, et al.
Publicado: (2013)

Reversible istradefylline-induced pleurothotonus in a patient with Parkinson's disease: A case report and literature review
por: Yasuda, Yuzuru
Publicado: (2018)

Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
por: Cummins, Lauren, et al.
Publicado: (2022)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

A Randomized, Double‐Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease
por: Rascol, Olivier, et al.
Publicado: (2022)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Phase 1/1b Studies of UCB0599, an Oral Inhibitor of α‐Synuclein Misfolding, Including a Randomized Study in Parkinson's Disease
por: Smit, Johan Willem, et al.
Publicado: (2022)

Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study
por: Hatano, Taku, et al.
Publicado: (2022)

Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial
por: Lipsmeier, Florian, et al.
Publicado: (2018)

Understanding the potential value of cardiovascular brain death donors to increase the heart donor pool
por: Brozzi, Nicolas A., et al.
Publicado: (2022)

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
por: Quattrone, Andrea, et al.
Publicado: (2022)

Shared Metabolic Profile of Caffeine in Parkinsonian Disorders
por: Takeshige‐Amano, Haruka, et al.
Publicado: (2020)

Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics
por: Bandres‐Ciga, Sara
Publicado: (2022)

Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression
por: Christine, Chadwick W., et al.
Publicado: (2020)

The Parkinson's Disease DNA Variant Browser
por: Kim, Jonggeol J., et al.
Publicado: (2021)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

The Myelin‐Weighted Connectome in Parkinson's Disease
por: Boshkovski, Tommy, et al.
Publicado: (2021)

Istradefylline Mitigates Age-Related Hearing Loss in C57BL/6J Mice
por: Shin, Min, et al.
Publicado: (2021)

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
por: Vila, Miquel
Publicado: (2019)

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

GP2: The Global Parkinson's Genetics Program
Publicado: (2021)

Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
por: Dommershuijsen, Lisanne J., et al.
Publicado: (2020)

Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review
por: Carey, Guillaume, et al.
Publicado: (2020)

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource
por: Iwaki, Hirotaka, et al.
Publicado: (2021)

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
por: Filippi, Massimo, et al.
Publicado: (2022)

A Multi‐Step Model of Parkinson's Disease Pathogenesis
por: Le Heron, Campbell, et al.
Publicado: (2021)

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
por: Omer, Nurit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_auteof0bpabna5653ck600u17p